In addition, combination of traditional chemotherapy with FOXM1 inhibition likely improves the outcome of MLL-r AML patients and prevents or reduces the frequency of relapse after treatment, thereby benefiting MLL-r AML patients. This evidence concerns the gene FOXM1 and acute myeloid leukemia.